非DEFUSE-非DAWN患者晚期时间窗机械取栓与最佳药物治疗比较:多中心队列研究
这项瑞士5中心队列研究纳入2014至2021年间前循环大血管闭塞且发病6至24小时、不符合DEFUSE-3和DAWN标准的278例患者中的190例,其中102例接受机械取栓。采用倾向评分逆概率加权分析,取栓组90天功能预后更优(acOR 1.46),全因死亡风险更低(aOR 0.59),症状性颅内出血无显著差异。
要点
- 晚期时间窗前循环大血管闭塞患者中,约2/3不符合DEFUSE-3和DAWN纳入标准。
- 不符合DEFUSE-3和DAWN标准的患者中,机械取栓与更优的90天功能预后相关(acOR 1.46)。
- 机械取栓与90天全因死亡风险降低相关(aOR 0.59),症状性颅内出血无显著差异。
核心结论
- 在不符合DEFUSE-3和DAWN纳入标准的晚期时间窗前循环大血管闭塞患者中,机械取栓与更高的良好功能预后几率相关,且未增加症状性颅内出血发生率。
- 这些发现支持将更多患者纳入正在进行的、纳入标准更宽松的晚期时间窗机械取栓随机试验。
研究设计与样本
- 多中心队列研究,纳入2014至2021年间瑞士5家卒中中心收治的发病6至24小时前循环大血管闭塞成人患者。
- 共278例晚期时间窗前循环大血管闭塞患者,其中190例(68%)不符合DEFUSE-3和DAWN纳入标准并纳入分析,102例(54%)接受机械取栓。
- 采用倾向评分逆概率加权比较机械取栓组与单纯最佳药物治疗组。
主要发现
- 逆概率加权分析中,机械取栓组较单纯最佳药物治疗组功能预后更优(改良Rankin量表评分向低类别偏移:acOR 1.46 [1.02-2.10],P=0.04)。
- 机械取栓组较单纯最佳药物治疗组90天全因死亡风险更低(aOR 0.59 [0.37-0.93],P=0.02)。
- 症状性颅内出血发生率机械取栓组与单纯最佳药物治疗组分别为5%与2%,无显著差异(P=0.63)。
关键数值与推荐
- 不符合DEFUSE-3和DAWN纳入标准的晚期时间窗前循环大血管闭塞患者占2/3。
- 主要疗效终点为90天良好功能预后,定义为改良Rankin量表评分向低类别偏移。
- 主要安全终点为卒中发作7天内症状性颅内出血,次要安全终点为90天内全因死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed the efficacy and safety of mechanical thrombectomy (MT) in adult stroke patients with anterior circulation large vessel occlusion presenting in the late time window not fulfilling the DEFUSE-3 (Thrombectomy for Stroke at 6 to 16 Hours With Selection by Perfusion Imaging trial) and DAWN (Thrombectomy 6 to 24 Hours After Stroke With a Mismatch Between Deficit and Infarct trial) inclusion criteria. METHODS: Cohort study of adults with anterior circulation large vessel occlusion admitted between 6 and 24 hours after last-seen-well at 5 participating Swiss stroke centers between 2014 and 2021. Mismatch was assessed by computer tomography or magnetic resonance imaging perfusion with automated software (RAPID or OLEA). We excluded patients meeting DEFUSE-3 and DAWN inclusion criteria and compared those who underwent MT with those receiving best medical treatment alone by inverse probability of treatment weighting using the propensity score. The primary efficacy end point was a favorable functional outcome at 90 days, defined as a modified Rankin Scale score shift toward lower categories. The primary safety end point was symptomatic intracranial hemorrhage within 7 days of stroke onset; the secondary was all-cause mortality within 90 days. RESULTS: Among 278 patients with anterior circulation large vessel occlusion presenting in the late time window, 190 (68%) did not meet the DEFUSE-3 and DAWN inclusion criteria and thus were included in the analyses. Of those, 102 (54%) received MT. In the inverse probability of treatment weighting analysis, patients in the MT group had higher odds of favorable outcomes compared with the best medical treatment alone group (modified Rankin Scale shift: acOR, 1.46 [1.02-2.10]; P=0.04) and lower odds of all-cause mortality within 90 days (aOR, 0.59 [0.37-0.93]; P=0.02). There were no significant differences in symptomatic intracranial hemorrhage (MT versus best medical treatment alone: 5% versus 2%, P=0.63). CONCLUSIONS: Two out of 3 patients with anterior circulation large vessel occlusion presenting in the late time window did not meet the DEFUSE-3 and DAWN inclusion criteria. In these patients, MT was associated with higher odds of favorable functional outcomes without increased rates of symptomatic intracranial hemorrhage. These findings support the enrollment of patients into ongoing randomized trials on MT in the late window with more permissive inclusion criteria.
引用
- Dittrich TD, Sporns PB, Kriemler LF, et al. Mechanical Thrombectomy Versus Best Medical Treatment in the Late Time Window in Non-DEFUSE-Non-DAWN Patients: A Multicenter Cohort Study. Stroke. 2023. PMID: 36718751. doi:10.1161/STROKEAHA.122.039793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。